Repository corticotropin injection ( DrugBank: Corticotropin )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
13	Multiple sclerosis/Neuromyelitis optica	3
46	Malignant rheumatoid arthritis	1
84	Sarcoidosis	2
222	Primary nephrotic syndrome	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01906658 (ClinicalTrials.gov)	July 2013	15/7/2013	A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis	A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Repository corticotropin injection	Mallinckrodt	NULL	Completed	18 Years	80 Years	All	43	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03126760 (ClinicalTrials.gov)	May 22, 2017	4/4/2017	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Terminated	18 Years	N/A	All	35	Phase 4	United States
2	NCT01888354 (ClinicalTrials.gov)	April 2013	16/5/2013	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Multiple Sclerosis (MS)	Drug: H.P. Acthar Gel (repository corticotropin injection)	The University of Texas Health Science Center, Houston	NULL	Completed	18 Years	55 Years	Both	25	Phase 4	United States
3	NCT00986960 (ClinicalTrials.gov)	December 2009	29/9/2009	Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)	Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study	Multiple Sclerosis	Drug: repository corticotropin injection;Drug: Saline	University at Buffalo	NULL	Terminated	18 Years	65 Years	All	3	Phase 2	United States

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01966718 (ClinicalTrials.gov)	October 2013	14/10/2013	Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.	Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action	Rheumatoid Arthritis	Drug: Repository corticotropin injection	Arthritis Treatment Center, Maryland	NULL	Completed	18 Years	80 Years	All	8	Phase 4	United States

84. Sarcoidosis

---

Clinical trials : 149 /  Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02920710 (ClinicalTrials.gov)	February 1, 2019	29/9/2016	ACTHAR Therapy for Central Nervous System Sarcoidosis	ACTHAR Therapy for Central Nervous System Sarcoidosis	Sarcoidosis	Drug: Repository Corticotropin Injection	The Cleveland Clinic	Mallinckrodt	Withdrawn	N/A	N/A	All	0	Phase 4	United States
2	NCT02725177 (ClinicalTrials.gov)	July 2016	11/3/2016	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis;Panuveitis;Anterior Uveitis	Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension	The Cleveland Clinic	Mallinckrodt	Recruiting	18 Years	99 Years	All	20	N/A	United States

222. Primary nephrotic syndrome

---

Clinical trials : 285 /  Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01386554 (ClinicalTrials.gov)	August 2011	29/6/2011	Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients	A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)	Proteinuria;Idiopathic Membranous Nephropathy	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Completed	18 Years	N/A	All	60	Phase 4	United States;Canada;Chile;Mexico;Turkey

Back to top